liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group
Fdn IRCCS Ist Nazl Tumori, Italy.
Westfalische Wilhelms Univ Munster, Germany.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences. Karolinska Inst, Sweden.
Univ Nottingham, England.
Show others and affiliations
2018 (English)In: Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, E-ISSN 1432-0843, Vol. 81, no 3, p. 427-441Article, review/survey (Refereed) Published
Abstract [en]

An increasing number of manuscripts focus on the in vitro evaluation of established and novel anti-tumor agents in experimental models. Whilst the design of such in vitro assays is inherently flexible, some of these studies lack the minimum information necessary to critically evaluate their relevance or have been carried out under unsuitable conditions. The use of appropriate and robust methods and experimental design has important implications for generating results that are reliable, relevant, and reproducible. The Pharmacology and Molecular Mechanisms (PAMM) group of the European Organization for Research and Treatment of Cancer (EORTC) is the largest group of academic scientists working on drug development and bundle decades of expertise in this field. This position paper addresses all researchers with an interest in the preclinical and cellular pharmacology of anti-tumor agents and aims at generating basic recommendations for the correct use of compounds to be tested for anti-tumor activity using a range of preclinical cellular models of cancer.

Place, publisher, year, edition, pages
SPRINGER , 2018. Vol. 81, no 3, p. 427-441
Keywords [en]
Cellular pharmacology; Anticancer agents; Guidelines
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:liu:diva-145745DOI: 10.1007/s00280-017-3502-7ISI: 000426060100001PubMedID: 29285635OAI: oai:DiVA.org:liu-145745DiVA, id: diva2:1192525
Note

Funding Agencies|Associazione Italiana per la Ricerca sul Cancro, Milan (AIRC-IG) [15333]

Available from: 2018-03-22 Created: 2018-03-22 Last updated: 2018-03-22

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Linder, Stig
By organisation
Division of Drug ResearchFaculty of Medicine and Health Sciences
In the same journal
Cancer Chemotherapy and Pharmacology
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 74 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf